Skip to content

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

0.6286
Chimera Difficulty Score
a synthesis of Flesch-Kincaid, Coleman-Liau, SMOG, and Dale-Chall readability metrics
Dive Brief: - AstraZeneca said Friday its experimental antibody drug tozorakimab met its main goal in two Phase 3 trials in chronic obstructive pulmonary disease, helping reduce flare-ups in a broad range of people with the condition. - The data could help AstraZeneca’s drug reach more patients than the currently available biologics for COPD, Dupixent and Nucala, both of which are limited to those...
AstraZeneca's announcement highlights the success of its experimental antibody drug, tozorakimab, in two Phase 3 trials for COPD. The trial results suggest that the drug could potentially expand the patient reach beyond the currently available biologics Dupixent and Nucala, as it seems to be effective for a broader range of patients regardless of their eosinophil levels or smoking status. The success of tozorakimab challenges the disappointing results from similar IL-33 blockers in la...